{"id":4669,"date":"2001-07-30T19:23:42","date_gmt":"2001-07-30T18:23:42","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=4669"},"modified":"2014-06-11T17:22:20","modified_gmt":"2014-06-11T17:22:20","slug":"ritonavir-approved-in-europe-as-pharmacokinetic-enhancer-for-use-with-other-antiretrovirals","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/4669","title":{"rendered":"Ritonavir approved in Europe as pharmacokinetic enhancer for use with other antiretrovirals"},"content":{"rendered":"<p><strong>Paul Blanchard, HIV i-Base<\/strong><\/p>\n<p><strong>Abbott Laboratories announced 2nd July that the European Agency for the Evaluation of Medicinal Products (EMEA) has approved a variation in indication for ritonavir (Norvir).<\/strong><\/p>\n<p>The newly approved indication permits the usage of ritonavir with other antiretroviral agents, including other protease inhibitors. This brings the licensed indication into line with the widespread current off-label use of this agent as a PK enhancer in regimens including dual (and triple) PI combinations. Such enhanced or boosted protease inhibitor combinations improve convenience by reducing dosing frequency and may facilitate long-term adherence.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paul Blanchard, HIV i-Base Abbott Laboratories announced 2nd July that the European Agency for the Evaluation of Medicinal Products (EMEA) has approved a variation in indication for ritonavir (Norvir). The newly approved indication permits the usage of ritonavir with other &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-4669","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=4669"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4669\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=4669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=4669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=4669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}